Prevent immunogenicity surprises

in the clinic.

Get Started
Who We Are

Fearless Science.

EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, we employ a wide range of validated in silico and in vitro techniques. This comprehensive approach provides accurate and thorough insights into candidate immunogenicity, ensuring the effectiveness and safety of our clients’ products.

Learn More

12M+

sequences analyzed

17

of the 20 top pharmaceutical companies served

500+

industry, agency, & academic collaborators

26

years experience

220+

peer-reviewed publications
News

 “EpiVax is an excellent company to work with. Their services were flexible to match our needs and communications were always prompt.”

 

– Chris Bai, CEO, AmbioPharm, Inc.

“The interactions with EpiVax were on a different level. On one side we have specific projects, on the other side, we had the possibility to train our people in the area of interest. Our scientists consistently benefit from these interactions, including webinars and on-site visits. All EpiVax people we have been exposed to are not only at a high scientific level but also able to establish good personal relationships.”

 

– Walter Cabri, Senior Vice President API I&D, Fresenius Kabi

“I couldn’t be more pleased with the results and the quality of EpiVax reporting. I look forward to continuing to work together.”

 

– Product Development Manager, U.S. Pharmaceutical Company

“We are very pleased with the detail-oriented scientific reports, timeliness, transparency, and accomodating nature of the EpiVax team. We can always count on the EpiVax team when we need them.”

 

– Simrat Singh, President, AmbioPharm, Inc. 

“EpiVax scientists were very responsive to our needs. They provided important insight into the project and delivered a comprehensive and articulate report.”

 

– Carl Spana, President & CEO, Palatin Technologies

“The report is very good and beneficial for our work. We have found EpiVax’s science to be very highly sophisticated and have learned a great deal from our discussions. We are deeply grateful.”

 

– Assistant General Manager Vaccine & Biomedical Research Dept., Japanese Biomedical Company

“The EpiVax analysis was helpful in that it formed part of the due diligence package presented to potential partners/investors in 2022. As a result, [COMPANY] was acquired and our lead molecule that EpiVax analyzed is in pre-clinical development. We have completed GMP manufacture, with IND submission planned in 2025.”

 

– Consultant & Former CSO, British Biomedical Company